|
|
|
| Dec. 14, 2007 |
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
|
| Dec. 10, 2007 |
Pivotal Phase 3 Nplate(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
|
| Dec. 8, 2007 |
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
|
| Dec. 6, 2007 |
Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs
|
| Dec. 5, 2007 |
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
|
| Dec. 4, 2007 |
Amgen Foundation and Leading Universities Invite College Students to Apply for Amgen Scholars Program
|
| Nov. 30, 2007 |
Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients
|
| Nov. 15, 2007 |
Amgen Announces ``My Cancer Coach'' Contest Winners at the College Hoops Classic
|
| Nov. 8, 2007 |
Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS' National Coverage Determination on ESAs
|
| Nov. 8, 2007 |
Amgen Announces Updates to the U.S. Prescribing Information for ESAs
|
| Nov. 7, 2007 |
New Data Show That Half of Patients with Active Early Rheumatoid Arthritis Achieved Clinical Remission at One Year When Treated with Enbrel(R) (etanercept) Plus Methotrexate
|
| Oct. 25, 2007 |
Amgen Foundation Donates $500,000 To Aid In Southern California Wildfire Relief Efforts
|
| Oct. 24, 2007 |
Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08
|
| Oct. 23, 2007 |
Jury Rules Roche Infringes Amgen's EPO Patents
|
| Oct. 16, 2007 |
Amgen Announces Webcast of 2007 Third Quarter Financial Results
|
| Oct. 4, 2007 |
Amgen and Dompe Biotec to Combine Commercial Operations in Italy
|
| Oct. 3, 2007 |
Amgen to Postpone Indefinitely Its Plans for a Manufacturing Facility in Ireland
|
| Oct. 2, 2007 |
Amgen Appoints Vance D. Coffman to the Company's Board of Directors
|
| Sep. 28, 2007 |
Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference
|
| Sep. 28, 2007 |
Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia
|
| Sep. 27, 2007 |
Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
|
| Sep. 26, 2007 |
Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing
|
| Sep. 26, 2007 |
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
|
| Sep. 25, 2007 |
New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
|
| Sep. 25, 2007 |
Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting
|
| Sep. 21, 2007 |
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
|
| Sep. 21, 2007 |
Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology
|
| Sep. 11, 2007 |
Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
|
| Sep. 6, 2007 |
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
|
| Sep. 5, 2007 |
Amgen Foundation Awards Grant to Mentor LA to Help Improve Public High School Education in Los Angeles
|
| Aug. 28, 2007 |
Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents
|
| Aug. 15, 2007 |
Amgen Restructures Due to Lower Aranesp(R) Revenues While Continuing to Invest in Innovation and Future Growth
|
| Aug. 15, 2007 |
Amgen to Hold Conference Call Today after the Close of Financial Markets
|
| Aug. 7, 2007 |
First Year Amgen Scholars and Leading Scientists Attend Symposium to Explore Drug Discovery & Development
|
| Aug. 1, 2007 |
Dennis Fenton, Executive Vice President of Operations, Elects to Retire after 25 Years with Amgen
|
| Jul. 31, 2007 |
Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology
|
| Jul. 26, 2007 |
Amgen's Second Quarter 2007 Adjusted Earnings Per Share Increased 7 Percent to $1.12
|
| Jul. 18, 2007 |
Amgen Completes Acquisition of Ilypsa
|
| Jul. 16, 2007 |
Amgen Completes Acquisition of Alantos
|
| Jul. 11, 2007 |
Amgen and Daiichi Sankyo Announce Agreement for Denosumab in Japan
|
| Jul. 11, 2007 |
Amgen Announces Webcast of 2007 Second Quarter Financial Results
|
| Jun. 28, 2007 |
Ralph Lauren Center for Cancer Care and Prevention Receives $2.5 Million from the Amgen Foundation to Launch National Patient Navigation Training Institute
|
| Jun. 26, 2007 |
Amgen Submits Testimony to House Ways & Means Committee
|
| Jun. 13, 2007 |
ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
|
| Jun. 6, 2007 |
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
|
| Jun. 4, 2007 |
Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care
|
| Jun. 2, 2007 |
Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision
|
| May. 29, 2007 |
Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
|
| May. 25, 2007 |
Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)
|
| May. 24, 2007 |
Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock
|
| May. 23, 2007 |
Amgen to Offer $4 Billion in Three Series of Senior Notes; Company to Purchase Approximately $3 Billion in Common Stock
|
| May. 22, 2007 |
Amgen Names David Lacey, M.D., Senior Vice President, Head of Research
|
| May. 18, 2007 |
Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
|
| Apr. 30, 2007 |
Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published
|
| Apr. 23, 2007 |
Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion
|
| Apr. 19, 2007 |
Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
|
| Apr. 18, 2007 |
2007 Recipients of Amgen Award for Science Teaching Excellence Announced
|
| Apr. 16, 2007 |
Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
|
| Apr. 11, 2007 |
Amgen Announces Webcast of 2007 First Quarter Financial Results
|
| Apr. 10, 2007 |
Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer
|
| Mar. 22, 2007 |
Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial Evaluating Vectibix(TM) As Part Of Triple Combination Regimen
|
| Mar. 19, 2007 |
Amgen to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference
|
| Mar. 12, 2007 |
Amgen to Present at the 27th Annual Cowen & Company Health Care Conference
|
| Mar. 9, 2007 |
Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
|
| Mar. 2, 2007 |
Prime Minister Tony Blair Opens Major Amgen Development Centre in London
|
| Feb. 28, 2007 |
Amgen to Participate in Oncologic Drugs Advisory Committee in May
|
| Feb. 28, 2007 |
Amgen to Participate in Goldman Sachs 'In Your Office' Call
|
| Feb. 16, 2007 |
Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study
|
| Feb. 15, 2007 |
Amgen Announces Proposals to Declassify Board to Be Presented at 2007 Annual Meeting and Adopts Majority Vote Bylaw
|
| Feb. 6, 2007 |
Amgen CEO Kevin Sharer to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
|
| Feb. 2, 2007 |
Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated
|
| Jan. 31, 2007 |
Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032
|
| Jan. 25, 2007 |
Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion
|
| Jan. 16, 2007 |
Amgen Launches 2007 Breakaway from Cancer Initiative
|
| Jan. 11, 2007 |
Amgen Announces Webcast of 2006 Fourth Quarter and Full Year Financial Results
|
| Jan. 3, 2007 |
Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure
|
